Literature DB >> 7672799

Different distribution of plexiform lesions in primary and secondary pulmonary hypertension.

B M Jamison1, R P Michel.   

Abstract

Despite much interest in plexiform lesions, no published work compares their distribution in different types of pulmonary hypertension. Scattered reports of plexiform lesions in bronchial arteries oppose the consensus view that the lesions develop in pulmonary arteries. To compare the localization of plexiform lesions in different types of pulmonary hypertension, and to assess the role of the bronchial arteries in their formation, we examined by light microscopy lung tissue from five patients with primary plexogenic pulmonary arteriopathy (PPPA), six with pulmonary hypertension secondary to congenital cardiac malformations (CCM), and one with pulmonary hypertension complicating hepatic cirrhosis. We classified the 270 plexiform lesions observed as either preacinar or intra-acinar based on the type of pulmonary artery in which they were located, and computed the frequencies of each type of lesion within each etiologic group. We searched for lesions developing in bronchial arteries. Then, postulating that a close anatomic relationship between plexiform lesions and bronchial arteries would necessitate a clustering of the lesions near sites in the lung subserved by the bronchial circulation, we measured, for 211 of the 270 lesions previously classified, the distance from the lesion to the nearest airway and computed the mean lesion-to-airway distance in each etiologic group. The frequencies of preacinar plexiform lesions were 34% in PPPA, 67% in CCM (P < .01), and 21% in the case of cirrhosis. We found no plexiform lesions within bronchial arteries, and the mean plexiform lesion-to-airway distances were 1,680 +/- 180 microns in PPPA, 1,330 +/- 220 microns in CCM, and 2,050 +/- 1,090 microns in cirrhosis (P > .05). Our data suggest that (1) the distribution of plexiform lesions within the pulmonary arterial tree varies depending on the etiology, (2) plexiform lesions rarely if ever arise in bronchial arteries, and (3) plexiform lesions are not preferentially distributed near parts of the lung subserved by the bronchial circulation.

Entities:  

Mesh:

Year:  1995        PMID: 7672799     DOI: 10.1016/0046-8177(95)90088-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.

Authors:  C D Cool; J S Stewart; P Werahera; G J Miller; R L Williams; N F Voelkel; R M Tuder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension.

Authors:  Yu Yamashita; Ichizo Tsujino; Takahiro Sato; Asuka Yamada; Taku Watanabe; Hiroshi Ohira; Masaharu Nishimura
Journal:  World J Hepatol       Date:  2014-11-27

Review 3.  Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT).

Authors:  Inna Krynytska; Mariya Marushchak; Anna Mikolenko; Anzhela Bob; Iryna Smachylo; Ludmyla Radetska; Olga Sopel
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

4.  Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension.

Authors:  Jennifer E Pogoriler; Stuart Rich; Stephen L Archer; Aliya N Husain
Journal:  Histopathology       Date:  2012-10       Impact factor: 5.087

Review 5.  Perspective: pathobiological paradigms in pulmonary hypertension, time for reappraisal.

Authors:  Rubin M Tuder; Kurt R Stenmark
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-18       Impact factor: 5.464

6.  Aneurysm-type plexiform lesions form in supernumerary arteries in pulmonary arterial hypertension: potential therapeutic implications.

Authors:  Kaori Oshima; Edward S Crockett; Sachindra R Joshi; Jared M McLendon; Yuri Matsumoto; Ivan F McMurtry; Kohtaro Abe; Masahiko Oka
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-02       Impact factor: 5.464

7.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

8.  GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells.

Authors:  Nils Nickel; Danny Jonigk; Tibor Kempf; Clemens L Bockmeyer; Lavinia Maegel; Johanna Rische; Florian Laenger; Ulrich Lehmann; Clemens Sauer; Mark Greer; Tobias Welte; Marius M Hoeper; Heiko A Golpon
Journal:  Respir Res       Date:  2011-05-06

9.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension.

Authors:  Sarfraz Saleemi; Majdy M Idrees
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.